Brief: Timber Pharmaceuticals Reports Positive Top-Line Results From Phase 2B Control Study Evaluating Tmb-001 In Moderate To Severe Congenital Ichthyosis

Trex Wind-Down

07/10/2021 14:13

Oct 7 (Reuters) - Timber Pharmaceuticals Inc  TMBR.A :
    * TIMBER PHARMACEUTICALS REPORTS POSITIVE TOP-LINE RESULTS
FROM
PHASE 2B CONTROL STUDY EVALUATING TMB-001 IN MODERATE TO SEVERE
CONGENITAL ICHTHYOSIS
    * TIMBER PHARMACEUTICALS INC - DATA DEMONSTRATE REDUCTION IN
TARGETED AND OVERALL SEVERITY OF CI IN PATIENTS TREATED WITH
TOPICAL IPEG TMB-001
    * TIMBER PHARMACEUTICALS INC - PLANNING FOR END-OF-PHASE 2
MEETING
WITH FDA IN BEGINNING OF 2022
    * TIMBER PHARMACEUTICALS INC - PHASE 3 STUDY IS EXPECTED TO
BEGIN
IN Q2 2022

Source text for Eikon:  ID:nGNE91FpzM 
Further company coverage:  TMBR.A 

 ((Reuters.Briefs@thomsonreuters.com;))